Ciclesonide for COVID-19
Ciclesonide has been reported as potentially beneficial for early treatment of COVID-19. We have not reviewed these studies. See all other treatments.
Ciclesonide Inhaler Treatment for Mild-to-Moderate COVID-19: A Randomized, Open-Label, Phase 2 Trial, Journal of Clinical Medicine, doi:10.3390/jcm10163545 ,
Efficacy of Inhaled Ciclesonide for Outpatient Treatment of Adolescents and Adults With Symptomatic COVID-19, JAMA Internal Medicine, doi:10.1001/jamainternmed.2021.6759 ,
FDA-Approved Drugs with Potent In Vitro Antiviral Activity against Severe Acute Respiratory Syndrome Coronavirus 2, Pharmaceuticals, doi:10.3390/ph13120443 ,
Variations of SARS-CoV-2 in the Iranian Population and Candidate Putative Drug-like Compounds to Inhibit the Mutated Proteins, Heliyon, doi:10.1016/j.heliyon.2022.e09910 ,
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.